Immundiagnostik Ag

Other

Armbruster Biotechnology Gmbh

Ifp Privates Institut Fur Produktqualitat Gmbh

Biomedica Gmbh

Charité – Universitätsmedizin Berlin

Johannes Gutenberg-Universität Mainz

Jochem, Ralf

Franz Paul Armbruster

Berthold Hocher

Mats Paulsson

Markus Karmatschek

Wolfgang Voelter

Felix Walzer

Ulf Joerg Forssmann

Ben John

Jens Tampe

Martin R Berger

Claudia Schumann

Christian Birkmayer

Franz Werner Nader

Albert Missbichler

Veit Braun

Wolfgang Weber

Christoph Von Eichel-Streiber

Frank Heller

Heinz Juergen Roth

Thorsten Knoeller

Ralf Jochem

Hans J Gron

Heinz-Juergen Roth

Sabine Friedl

Rolf Briant

Heinrich Schmidt-Gayk

Heinz Jürgen Roth

Heinz-Jürgen Roth

Moritz Leppkes

Hans Juergen Groen

Pol Maria Rommens

Ulrike Ritz

Thomas B Dschietzig

Liliana Schaefer

Andreas Baranowski

Alexander Hofmann

Anja Klein

Timm H Westhoff

Hans Jürgen GRÖN

Wolfgang Ifp Privates Institut Für Weber

Max Diesner

Anne Arnold

Sonja Bastian

An analyte testing system for quantifying the presence of an analyte in a speciment by lateral flow chromatography. The system comprises a test cassette () with a lateral flow chromatography and a mobile hand-held processor device () comprising a digital camera (), a source of light () and a processor (), which software and hardware () are configured to determine automatically the distance between camera and object and the measures of light in the region of interest of the lateral flow chromatography prior any retrieval of image data for further analysis and quantification of the visual signals.

System for analyzing quantitative lateral flow chromatography

An analyte testing system for quantifying the presence of an analyte in a specimen by immunochromatography. The system comprises a camera test card, depicting a test cassette () with an immunochromatography and a handheld processor device () comprising a digital camera (), a source of light () and a processor (), which software and hardware () are configured to make a pose estimation of camera and object and the measures of light in the region of interest of the immunochromatography. The system allows an automatic camera calibration and certification as a scanner for use in point-of-care diagnostics.

Calibration of a digital camera for use as a scanner

A method for detecting and quantifying anti-neutrophil-cytoplasmic antibodies (ANCA) in a sample of bodily fluid from a patient suspected of suffering from an autoimmune disease, including the steps of contacting human polymorphonuclear neutrophils able to release extracellular traps (NETs) with microspheres to produce NET-coated microspheres, contacting the NET-coated microspheres with the sample of bodily fluid, and labeling and subsequent analyzing of anti-neutrophil-cytoplasmic antibodies by flow cytometric methods.

Method of measuring auto-antibodies in bodily fluids

A novel therapy concept based on a removal of circulating BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD) or highly at risk of developing arterial and vascular calcifications. The method comprises method of treatment of extracellular tissue and vascular calcifications, atherosclerosis, arteriosclerosis, and arterial calcification. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients as well as in animal models.

Method of treating extracellular tissue and vascular calcification and arteriosclerosis

A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG.shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt/V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other/unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng/L (IQR, 2.4 to 14.0 ng/L). n-oxPTH concentrations were not different in men and women (5.9 ng/L; IQR, 2.4 to 14.2 ng/L; n=224; vs. 5.5 ng/L; IQR, 2.4 to 14.0 ng/L; n=116; p=0.915).

Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients

A method is disclosed for obtaining an antibody or antibody fragment to a conformational epitope specific for misfolded inactive human parathyroid hormone and fragments thereof. The method includes the steps of a) immunizing an animal with an immunogen which comprises oxidized parathyroid hormone or an oxidized fragment of parathyroid hormone, or both; and b) recovering an antibody, antibody fragments, or single chain antibody. The complementary determining region of the recovered antibody, antibody fragment or single chain antibody is capable of specifically recognizing a conformational epitope (antigenic determinant) which is present on oxidized parathyroid hormone and fragments thereof only but not regular bioactive human parathyroid hormone.

Means and methods of measuring parathyroid hormone in patients suffering from oxidative stress

The present invention provides a novel therapy concept based on a removal of circulation BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD), preferably by plasmapheresis or an administration of antibodies against BSP in plasma. The present invention further provides a BSP absorber material for plasmapheresis and a pharmaceutical composition namely in form of anti-BSP antibodies for direct administration which are biocompatible in humans. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients.

Medicament and apparatus for treating chronic kidney disease

Method of diagnosis and prognosis of contrast media induced nephropathy (CIN) including the steps of i) taking a urine sample from a patient exposed to the application of contrast media, notably patients subjected to coronary angiography; ii) assessing the level of vitamin D binding protein (VDBP) in the urine sample obtained in step (i); iii) relating the urinary vitamin D binding protein level determined in step (ii) to a pre-selected threshold level. A urinary vitamin D binding protein level higher than the pre-selected threshold level indicates that the patient is at risk of renal failure and in need of a dialysis treatment.

In vitro diagnostic and prognosis of major adverse events in patients undergoing coronary angiography

Method and test kit for quantitative determination of Vitamin D metabolites in blood, wherein a predetermined amount of blood is pre-analytically immobilized on a solid sorption material. Thereby, hemolysis of the blood has no effect on the analysis of vitamin D metabolites. For quantitative analysis the dried blood spot on the sorption material is dissolved with an aqueous solvent buffer containing detergent, pH 7.0 to 10.0, and the vitamin D metabolites are eluted with a protic organic solution having a permittivity of less than 35. The eluate is analyzed for vitamin D metabolites using conventional methods.

Determination of vitamin D metabolites in dried blood

A bone graft or biocomposite for treating osseous defects and neogenesis of bone which is a composite of a biodegradable polymer and granules of beta-tricalciumphosphate, further comprising as active ingredient and embedded in the biodegradable polymer a physiologically effective amount of underglycosylated recombinant human BSP as a multi-dental clathrate with a basic organic compound which simulataneously is active as a plasticizer for the biodegradable polymer. The biocomposite is moldable and shapeable, hardens rapidly in situ when placed by surgery or prosthetic dentistry and which furthers osseous repair and the healing of damage or diseased tissues and lesions.

Bone graft and biocomposite for prosthetic dentistry

The invention relates to a method of therapy against tumors and their metastases, which preferentially settle in bone tissue, comprising administering to a patient in need thereof an active ingredient which comprises at least one binding molecule that binds to human bone sialoprotein or a fragment thereof.

Method for treating tumors and their metastases

Method for the quantitative determination of vitamins, amino acids, or other substances necessary for life, in a substance mixture, whereby in the culture container, the cavities of a microtitration plate, in each case a predetermined number of vital cells of a suitable microorganism are prepared in a permanent manner. For this purpose, the cells are shock frozen at &#x2212;80&#xb0; C. and then freeze dried in a freezing solution containing 200 to 500 mM trehalose/sucrose. The freezing solution is preferably the test medium. The culture containers are preferably the wells of a microtitration plate.

Method and kit for the microbiological determination of vitamins in substance mixtures

The invention is relates to drugs on the basis of antibodies against non-cellular bone matrix proteins, especially BSP, for use in the prevention and treatment of bone metastases. According to the invention, the antibodies are induced in the patient by recombinantly expressing antigenic determinants of bone matrix proteins inand anchoring them on the surfaces thereof. The antigenic determinants are selected according to whether they are characteristic of antigens that are expressed by the tumor cells themselves.

Therapeutic composition for use in the prevention and treatment of bone metastases

The preparation of vitamin D compounds of formula (I) with a label attached to a spacer group in the 3 position is disclosed. In the above formula (I), O represents the oxygen atom of an ether group; Y represents hydrogen or hydroxy; A represents a label such as biotin, digoxigenin, or another vitamin D group; R represents a substituted hydrocarbon side-group of vitamin D or a vitamin D metabolite. Also disclosed is a method of measuring 25-hydroxy vitamin D metabolite and a 1&#x3b1;,25-dihydroxy vitamin D metabolite in a sample.

Functional vitamin D derivatives and method of determining 25-hydroxy- and 1&#x3b1;, 25-dihydroxy vitamin D

A method for quantitating vitamin D metabolites directly in blood plasma or serum, without the need for prior purification of the vitamin D metabolites, comprising a digestion of the serum proteins with a serine protease such as proteinase K and sequence of steps for inhibiting the proteinase K activity in the competitive binding analysis. The advantages of this method are its high accuracy over the whole range of physiologically relevant values and that it can be easily adapted for a fully automated analysis of serum and plasma samples.

Direct determination of vitamin D in serum or plasma

Growing community of inventors

Bensheim, Germany

Franz Paul Armbruster